Team
Dean Fennell, FRCP, PhD
Professor Dean Fennell is a clinician scientist and international leader in mesothelioma research. He has designed and led several investigator-initiated trials from phase 1 through phase III including the first precision medicine platform study for patients with mesothelioma (MIST).
He is past-president of the International mesothelioma interest group, past NCRI mesothelioma chair, co-author of UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines and served two terms on the EORTC board. His lab is currently pioneering novel precision medicine strategies and the study of tumour evolution in mesothelioma.
Professor Fennell held two CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at UCL , then completed training in London. Prof. Fennell has published 167 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, & Nature communications
In 2023 he was awarded the IMIG Senior Investigator medal and MARF Pioneer Award for his work in the field.